Genmab — Board/Management Information 2008

Sep 3, 2008

GENMAB ANNOUNCES CHANGE IN MANAGEMENT

Summary: Dr. Claus Møller steps down from his position as Chief Operating Officer of Genmab.

Copenhagen, Denmark; September 3, 2008 – Genmab A/S (OMX: GEN) announced today that Claus Møller, M.D., Ph.D. has informed the Board of Directors of his intention to step down from his position as Executive Vice President, Chief Operating Officer of Genmab. Dr. Møller's decision reflects his desire to concentrate on his role as Chairman of the board of IPC-International, Plc and to spend more time with his family having achieved his main career goals within Genmab.

Dr. Møller will remain available to Genmab as Development Advisor during a transitional period for the remainder of 2008. The Chief Operating Officer position at Genmab will be discontinued and Dr. Møller's responsibilities will be folded into the research and development department which has already been consolidated under the direction of Prof. Jan G. J. van de Winkel, Ph.D., President, Research and Development and Chief Scientific Officer, in conjunction with an earlier expansion of the company's senior management team which now includes eight members.

"Claus was one of Genmab's founders ten years ago and has been an essential part of building Genmab into a world leading biotechnology company. He has made significant contributions across a range of activities including the development of ofatumumab. We wish to offer our sincere thanks to Claus for his many years of service with the company and wish him the best in his future endeavors," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our

Genmab A/S Tel: +45 7020 2728 Stock Exchange Release no. 41/2008 Toldbodgade 33 Fax: +45 7020 2729 Page 1/2 1253 Copenhagen K, Denmark CVR no. 2102 3884

GENMAB ANNOUNCES CHANGE IN MANAGEMENT

patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD4®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™ and UniBody® are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations T: +45 33 44 77 30; M: +45 25 27 47 13; E: hth@genmab.com

###